Phosphodiesterase 2: anti-adrenergic friend or hypertrophic foe in heart disease?

被引:0
作者
Michael Wagner
Hind Mehel
Rodolphe Fischmeister
Ali El-Armouche
机构
[1] Technische Universität Dresden,Institut für Pharmakologie und Toxikologie
[2] Univ. Paris-Sud,INSERM UMR
[3] Université Paris-Saclay,S 1180
来源
Naunyn-Schmiedeberg's Archives of Pharmacology | 2016年 / 389卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1139 / 1141
页数:2
相关论文
共 21 条
[1]  
Bristow MR(1982)Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts N Engl J Med 307 205-211
[2]  
El-Armouche A(2009)Beta-adrenergic stimulation and myocardial function in the failing heart Heart Fail Rev 14 225-241
[3]  
Eschenhagen T(2008)Phosphatase inhibitor-1-deficient mice are protected from catecholamine-induced arrhythmias and myocardial hypertrophy Cardiovasc Res 80 396-406
[4]  
El-Armouche A(2006)Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases Circ Res 99 816-828
[5]  
Fischmeister R(1986)Opposite effects of cyclic GMP and cyclic AMP on Ca2+ current in single heart cells Nature 323 273-275
[6]  
Castro LR(2010)Activation of PDE2 and PDE5 by specific GAF ligands: delayed activation of PDE5 Br J Pharmacol 161 1645-1660
[7]  
Abi-Gerges A(2013)Phosphodiesterase-2 is up-regulated in human failing hearts and blunts beta-adrenergic responses in cardiomyocytes J Am CollCardiol 62 1596-1606
[8]  
Rochais F(1991)Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group N Engl J Med 325 1468-1475
[9]  
Jurevicius J(2015)Cardiac hypertrophy is inhibited by a local pool of cAMP regulated by phosphodiesterase 2 Circ Res 117 707-719
[10]  
Leroy J(undefined)undefined undefined undefined undefined-undefined